past
year
rna
interfer
rnai
becom
wide
use
experiment
tool
analys
function
mammalian
gene
vitro
vivo
har
evolutionari
conserv
endogen
biolog
pathway
first
identifi
plant
lower
organ
doublestrand
rna
dsrna
reagent
use
bind
promot
degrad
target
rna
result
knockdown
express
specif
gene
rnai
induc
mammalian
cell
introduct
synthet
doublestrand
small
interf
rna
sirna
base
pair
bp
length
plasmid
viral
vector
system
express
doublestrand
short
hairpin
rna
shrna
subsequ
process
sirna
cellular
machineri
rnai
wide
use
mammalian
cell
defin
function
role
individu
gene
particularli
diseas
addit
sirna
shrna
librari
develop
allow
systemat
analysi
gene
requir
diseas
process
cancer
use
high
throughput
rnai
screen
rnai
use
knockdown
gene
express
experiment
anim
develop
shrna
system
allow
tissuespecif
induc
knockdown
gene
promis
provid
quicker
cheaper
way
gener
transgen
anim
convent
approach
final
abil
rnai
silenc
diseaseassoci
gene
tissu
cultur
anim
model
develop
rnaibas
reagent
clinic
applic
gather
pace
technolog
enhanc
improv
sirna
stabil
deliveri
vivo
minimis
offtarget
nonspecif
effect
develop
modern
drug
discoveri
targetdriven
whittak
identif
gene
human
genom
spawn
vari
estim
number
potenti
new
drug
target
await
discoveri
drew
hopkin
groom
howev
translat
genom
inform
drug
therapi
still
major
challeng
face
pharmaceut
compani
provid
support
concept
drug
modul
given
target
like
produc
therapeut
respons
patient
key
step
progress
gene
screen
hardi
peet
main
limit
know
gene
product
function
involv
patholog
diseas
target
valid
druggabl
gene
product
small
molecul
compound
decad
target
mrna
target
valid
therapeut
strategi
activ
pursu
use
ribozym
breaker
antisens
crook
approach
date
antisens
technolog
produc
market
drug
vitraven
cytomegalovirusinduc
retin
winkler
rna
interfer
rnai
latest
entri
field
hail
scientif
breakthrough
year
journal
scienc
couzin
doublestrand
rna
dsrna
reagent
use
bind
promot
degrad
target
rna
har
endogen
biolog
pathway
context
drug
discoveri
valu
rnai
base
premis
knock
express
put
drug
target
use
rapidli
specif
simul
biolog
pharmacolog
effect
target
inhibit
lowmolecularweight
compound
cellular
assay
anim
model
diseas
although
still
infanc
respect
drug
develop
august
brought
file
acuiti
pharmaceut
us
food
drug
administr
first
clinic
trial
rnai
therapeut
treatment
common
form
blind
http
www
articl
review
assess
use
rnai
reagent
target
valid
potenti
therapeut
rnai
first
observ
plant
biologist
late
molecular
mechan
remain
unclear
late
eleg
work
nematod
caenorhabd
elegan
show
rnai
evolutionari
conserv
genesilenc
mechan
fire
et
al
reinhart
et
al
sequencespecif
posttranscript
gene
silenc
doublestrand
rna
conserv
rang
organ
plant
neurospora
drosophila
c
elegan
mammal
process
relat
normal
defens
virus
mobilis
transpos
genet
element
transposon
tijsterman
et
al
dsrna
produc
integr
transposon
replic
virus
one
newli
identifi
class
regulatori
noncod
microrna
mirna
bartel
process
short
dsrna
short
rna
trigger
cascad
biochem
event
fig
involv
cytoplasm
ribonucleas
iii
rnase
iii
like
protein
known
dicer
partial
characteris
multiprotein
complex
known
rnainduc
silenc
complex
risc
lead
ultim
degrad
mrna
posttranscript
gene
silenc
natur
occur
mirna
synthes
nucleu
larg
precursor
form
enzym
known
drosha
mediat
process
primari
mirna
transcript
premirna
export
cytoplasm
cytoplasm
dicer
respons
cleav
doublestrand
molecul
whether
deriv
endogen
mirna
replic
virus
small
rna
duplex
base
pair
bp
characterist
overhang
bernstein
et
al
small
interf
rna
sirna
duplex
incorpor
risc
whereupon
atpdepend
helicas
unwind
duplex
enabl
either
one
strand
independ
recogn
mrna
kisielow
et
al
extent
complementar
guid
strand
target
mrna
determin
whether
mrna
silenc
achiev
via
sitespecif
cleavag
messag
region
sirna
mrna
duplex
caudi
et
al
mirnalik
mechan
translat
repress
doench
et
al
sirnamedi
silenc
cleavag
product
releas
degrad
leav
disengag
risc
complex
survey
mrna
pool
although
genom
approach
gene
express
analysi
use
gene
chip
archacki
wang
diseas
gene
map
whittak
associ
gene
diseas
phenotyp
data
alon
defin
diseaseassoci
role
protein
encod
gene
knockout
mice
prove
power
way
studi
gene
biologicaldiseas
relev
rosahl
extent
knockout
phenotyp
show
good
correl
drug
efficaci
zambrowicz
et
al
howev
cost
time
implic
develop
model
mean
drive
develop
method
enabl
target
valid
vitro
particularli
work
novel
target
embark
vivo
studi
given
success
rnai
assign
gene
function
lower
eukaryot
nematod
worm
c
elegan
sugimoto
fruitfli
drosophila
melanogast
kuttenkeul
boutro
surpris
approach
adopt
analys
gene
function
particularli
target
valid
mammalian
system
specif
effect
silenc
gene
rnai
c
elegan
melanogast
achiev
use
long
bp
dsrna
mello
cont
furthermor
dsrna
introduc
worm
direct
inject
feed
bacteria
express
dsrna
soak
worm
solut
dsrna
wang
barr
howev
case
mammalian
system
firstli
dsrna
bp
trigger
ginterferon
ifn
pathway
interferon
pathway
one
arm
innat
immun
system
trigger
partli
dsrna
common
replic
intermedi
viral
infect
thu
bp
doublestrand
small
interf
rna
sirna
gener
chemic
synthesi
elbashir
et
al
enzymat
cleavag
kittler
et
al
express
system
zheng
et
al
use
molecul
elud
stress
respons
mimick
dicer
product
enter
rnai
pathway
downstream
secondli
sirna
duplex
transfect
mammalian
cell
use
either
lipidbas
formul
braza
hagstrom
electropor
gresch
et
al
link
peptid
muratovska
eccl
sirna
becom
wide
use
basic
structur
effect
sirna
defin
fig
includ
need
rna
duplex
overhang
also
becom
clear
effect
sirna
silenc
sequenc
specif
henc
rule
sirna
design
develop
mittal
reynold
et
al
despit
sirna
duplex
still
experiment
assess
optimis
knockdown
individu
mrna
molecul
duplex
match
design
criteria
potent
kumar
et
al
hsieh
et
al
also
emphasis
gene
express
knock
rather
knock
sirna
success
appli
mammalian
cell
line
caplen
et
al
elbashir
et
al
primari
cell
kao
et
al
krick
et
al
embryon
stem
cell
ikeda
et
al
hoelter
et
al
press
contrast
c
elegan
rnai
effect
stabl
long
last
pass
onto
offspr
grishok
mello
gene
silenc
transfect
sirna
duplex
mammalian
cell
transient
mammalian
cell
lack
rnadepend
rna
polymeras
amplifi
sirna
c
elegan
result
gene
silenc
depend
number
sirna
molecul
transfect
cell
duplex
becom
progress
dilut
cell
divid
persist
sirna
activ
mammalian
cell
vari
prolif
statu
cell
sirna
activ
last
day
prolifer
cell
persist
week
termin
differenti
cell
neuron
omi
et
al
get
around
problem
vectorbas
system
introduct
stabl
express
sirna
target
cell
develop
tuschl
vector
contain
rna
polymeras
iii
promot
either
express
sens
antisens
strand
separ
promot
tandem
type
express
short
hairpin
rna
shrna
cleav
dicer
produc
sirna
shrna
type
fig
stabli
transfect
cell
line
gener
select
drug
resist
marker
express
either
vector
cotransfect
plasmid
vector
system
success
use
obtain
effici
stabl
knockdown
target
gene
mammalian
cell
mittal
although
difficult
say
vector
system
effici
silenc
gene
express
work
suggest
shrna
system
effect
tandem
system
miyagishi
taira
recent
work
also
indic
shrna
potent
induc
rnai
sirna
siola
et
al
limit
use
plasmid
vector
term
effici
transfect
difficulti
transfect
primari
cell
dykxhoorn
et
al
result
worker
develop
retrovir
brummelkamp
et
al
lentivir
rubinson
et
al
adenovir
art
et
al
vector
system
shrna
deliveri
viral
vector
permit
effici
deliveri
stabl
express
shrna
construct
rang
mammalian
cell
includ
primari
cell
varieti
anim
speci
retrovir
vector
base
murin
stem
cell
viru
moloney
murin
leukemia
viru
permit
stabl
introduct
shrna
divid
cell
transform
primari
use
suppress
gene
express
stem
cell
reconstitut
organ
deriv
cell
hemann
et
al
lentivir
vector
deriv
human
immunodefici
viru
hiv
infect
divid
nondivid
postmitot
cell
eg
neuron
use
gener
transgen
anim
display
lossoffunct
phenotyp
vector
transmiss
offspr
rubinson
et
al
tiscornia
et
al
adenovir
vector
base
adenoassoci
virus
aav
infect
divid
nondivid
cell
integr
site
specif
region
chromosom
safer
retrovir
lentivir
vector
associ
insert
mutagenesi
mittal
aav
vector
success
use
silenc
gene
vitro
vivo
xia
et
al
boden
et
al
rnai
use
knockdown
gene
express
anim
promis
provid
quicker
cheaper
way
gener
knockout
anim
deliveri
sirna
model
mammalian
organ
achiev
intraven
inject
electropor
synthet
sirna
directli
target
tissu
organ
dillon
et
al
howev
effici
stabl
silenc
effect
obtain
use
retrovir
lentivir
vector
transduc
stem
cell
embryo
hemann
et
al
rubinson
et
al
result
experi
number
laboratori
show
sirnamedi
gene
silenc
function
rang
cell
tissu
type
blastocyst
adult
anim
herit
stabl
kunath
et
al
transfect
mous
es
cell
construct
express
shrna
ra
gtpaseactiv
protein
rasgap
abl
produc
mice
die
embryogenesi
defect
similar
rasgap
knockout
mice
produc
homolog
recombin
anoth
studi
mrna
level
tcell
reduc
transgen
mice
made
use
fig
tandem
hairpintyp
express
vector
rnai
tandemtyp
vector
sens
antisens
strand
express
separ
polymeras
iii
promot
strand
anneal
insid
cell
form
duplex
sirna
molecul
hairpintyp
vector
sens
antisens
strand
connect
loop
express
singl
molecul
rapidli
form
hairpin
structur
stem
loop
process
sirna
dicer
lentivir
vector
express
hairpin
rubinson
et
al
gener
mice
technic
easier
gener
knockout
mice
tradit
rout
furthermor
find
approach
appli
speci
amen
embryon
stem
cell
gene
target
rat
hasuwa
et
al
particularli
use
indic
knockdown
phenotyp
produc
rnai
may
varieg
tradit
knockout
phenotyp
kunath
et
al
rubinson
et
al
may
use
model
complex
human
diseas
suscept
resist
encod
gene
variant
display
rel
rather
absolut
differ
express
cellspecif
target
sishrna
express
import
consider
particularli
consid
rnai
therapeut
applic
van
haaften
et
al
altern
lowmolecularweight
molecul
target
valid
vivo
get
around
lethal
effect
knock
gene
crucial
develop
induc
knockout
system
use
kwak
et
al
vector
carri
induc
promot
allow
control
express
shrna
respons
induc
base
pol
iii
promot
control
tetracyclin
matsukura
et
al
ecdyson
gupta
et
al
caus
recombin
cre
recombinas
wiznerowicz
trono
fritsch
et
al
kasim
et
al
tiscornia
et
al
develop
sirna
system
combin
cre
loxp
tissuespecif
express
tetracyclineon
induc
express
describ
recent
mate
one
mous
carri
sirnaloxp
plasmid
anoth
mous
carri
cre
recombinas
specif
tissu
sirna
offspr
induc
tetracyclin
use
method
mous
line
mimick
tangier
diseas
produc
without
need
use
embryon
stem
cell
gene
target
although
product
transgen
mice
rnai
potenti
provid
speedi
way
produc
knockout
anim
well
characteris
knockout
approach
unclear
technolog
robust
enough
gener
approach
vivo
studi
detail
analys
perform
determin
reliabl
gene
function
knock
tissu
time
throughout
life
anim
level
knockdown
requir
result
phenotyp
lentivir
approach
often
result
multipl
integr
event
rubinson
et
al
tiscornia
et
al
mosaic
express
shrna
might
expect
one
excit
opportun
offer
rnai
facil
identifi
gene
requir
certain
physiolog
process
use
genomewid
rnai
screen
carpent
sabatini
silva
et
al
highthroughput
screen
identifi
gene
involv
develop
carcinogenesi
success
carri
c
elegan
lettr
et
al
poulin
et
al
melanogast
lum
et
al
dasgupta
perrimon
web
databas
archiv
distribut
rnai
data
organ
develop
wwwrnaiorg
wwwflyrnaiorg
abil
extend
screen
mammalian
system
potenti
power
gene
identifi
level
accuraci
henc
possibl
defin
role
gene
cellbas
phenotyp
assay
systemat
inhibit
gene
express
although
synthet
sirna
compat
highthroughput
format
vanheck
janitz
genomescal
librari
chemic
synthes
sirna
report
howev
smaller
collect
screen
gene
azablanc
et
al
hsieh
et
al
sirna
librari
target
human
gene
base
express
system
sirna
duplex
gener
upon
transfect
mammalian
cell
use
identifi
regul
nuclear
factorkappab
nfnb
signal
zheng
et
al
effort
area
concentr
use
vectorbas
shrna
librari
vanheck
janitz
largescal
geneknockdown
studi
use
retrovir
vector
express
shrna
report
mammalian
cell
bern
et
al
paddison
et
al
studi
includ
molecular
bar
code
vector
individu
shrna
cell
could
easili
detect
screen
identifi
new
member
pathway
analys
howev
failur
detect
certain
known
member
pathway
highlight
current
limit
approach
adenovir
vector
use
gener
shrna
librari
aim
knock
nearli
transcript
encod
druggabl
protein
http
wwwgaladenocom
potenti
genomewid
screen
could
carri
process
tissu
cultur
model
exist
furthermor
develop
transfect
cell
array
sishrna
print
onto
modifi
glass
surfac
vanheck
janitz
provid
way
reduc
reagent
usag
cost
larg
screen
erfl
et
al
larg
amount
phenotyp
data
aris
largescal
knockdown
studi
requir
develop
bioinformat
tool
transform
complex
dataset
digitis
format
readili
mine
gunsalu
piano
use
rna
interfer
studi
diseaseassoci
gene
sirna
wide
use
mammalian
cell
defin
function
role
individu
gene
particularli
diseas
dykxhoorn
et
al
dillon
et
al
sirna
extens
use
cellbas
studi
pathway
dissect
semizarov
et
al
sun
et
al
siripurapu
et
al
knockdown
express
gene
involv
rang
cellular
process
includ
endocytosi
huang
et
al
signal
transduct
debe
et
al
shu
et
al
apoptosi
kartasheva
et
al
lassu
et
al
cell
cycl
chen
et
al
well
gene
relev
neurodegen
diseas
alberi
et
al
buckingham
et
al
thakker
et
al
yokota
et
al
xenotransplant
karla
et
al
section
concentr
use
rnai
studi
diseaserelev
gene
cancer
infect
respiratori
diseas
success
drug
gleevec
imatinib
shown
effect
directli
target
cancerpromot
protein
cancer
therapi
revolution
drug
therapi
chronic
myelogen
leukemia
cml
deining
et
al
howev
drug
resist
common
advanc
phase
diseas
mutat
kinas
domain
bcr
abl
fusion
protein
impair
imatinib
bind
fusion
protein
attract
candid
rnai
shown
sirna
molecul
target
junction
fusion
sequenc
attenu
prolifer
transform
haematopoiet
cell
sensitis
cell
imatinib
also
inhibit
imatinib
mutant
abil
sirna
silenc
specif
oncogen
variant
spare
wildtyp
product
gene
demonstr
kra
human
pancreat
carcinoma
brummelkamp
et
al
similarli
singl
point
mutat
tumour
suppressor
effect
discrimin
use
sirna
martinez
et
al
result
target
destruct
mutant
wildtyp
product
uterin
cancer
specif
knockdown
akt
isoform
use
sirna
technolog
shown
significantli
reduc
resist
endometri
kle
cell
cisplatininduc
apoptosi
gagnon
et
al
receptor
associ
certain
mitogen
pathway
known
promot
malign
exampl
stimul
gonadotropin
receptor
activ
mitogenactiv
protein
kinas
mapk
cascad
shown
enhanc
develop
wide
rang
gynaecolog
malign
includ
ovarian
breast
endometri
carcinoma
freimann
et
al
chemokin
receptor
chemokin
cx
c
motif
receptor
breast
cancer
cell
line
specif
target
sirna
rate
cell
expans
slow
dramat
lapteva
et
al
furthermor
h
integrin
lipscomb
et
al
epcam
osta
et
al
receptor
cell
identifi
rna
interfer
involv
cellular
invas
metastasi
prostat
cancer
androgen
receptor
shown
essenti
androgeninduc
downregul
oncogen
bcell
chronic
lymphocyt
leukemialymphoma
express
use
sirna
direct
sever
gene
encod
protein
involv
androgen
signal
pathway
huang
et
al
select
regul
express
cancerassoci
gene
evolv
anoth
potenti
therapeut
approach
clusterin
antiapoptot
protein
commonli
express
cancer
cell
refractori
convent
chemotherapi
use
cell
juli
et
al
show
strong
correl
sirnamedi
reduct
clusterin
protein
chemosensit
cell
vitro
perhap
wellstudi
member
class
antiapoptot
protein
survivin
whose
express
level
shown
directli
proport
tumour
grade
recurr
risk
surviv
patient
bladder
cancer
ambrosini
et
al
ning
et
al
demonstr
survivin
sirna
promot
apoptosi
inhibit
surviv
bladder
cancer
cell
gene
encod
multidrugresist
protein
mdr
pump
chemotherapeut
drug
tumour
stege
et
al
telomeras
involv
overcom
chromosom
shorten
occur
cell
divis
et
al
make
cell
resist
caspasemedi
apoptosi
yin
et
al
exampl
gene
mutat
cancer
overexpress
varieti
cancer
repres
attract
target
silenc
dna
repair
mechan
crucial
mainten
genom
stabil
emerg
potenti
therapeut
target
cancer
chow
et
al
use
sirna
identifi
endoexonucleas
protein
involv
recombin
repair
process
dna
doublestrand
break
pathway
overexpress
varieti
cancer
cell
potenti
anticanc
target
signal
molecul
intens
research
potenti
therapeut
target
cancer
instanc
braf
serinethreoninespecif
protein
kinas
mutat
human
melanoma
braf
link
extracellular
signal
regul
protein
kinas
erk
signal
promot
prolifer
antiapoptot
wellbrock
et
al
karasarid
et
al
show
braf
deplet
sirna
block
erk
activ
inhibit
dna
synthesi
induc
apoptosi
three
melanoma
cell
line
mani
studi
indic
rho
gtpase
import
malign
transform
angiogenesi
repres
good
anticanc
target
aznar
et
al
pill
et
al
use
antirhoa
antirhoc
sirna
block
rhosignal
pathway
demonstr
sirna
inhibit
cell
prolifer
invas
effect
convent
blocker
rho
signal
eg
hmgcoa
reductas
inhibitor
vitro
vivo
report
vivo
experi
sirna
cancer
grow
nude
mice
implant
colon
adenocarcinoma
cell
surviv
mice
greatli
prolong
pretreat
cell
sirna
hcatenin
similarli
silenc
oncogen
hra
led
inhibit
vivo
tumour
growth
human
ovarian
cancer
mice
avail
genom
sequenc
rang
pathogen
virus
http
wwwncbinlmnihgovgenom
virusesviruseshtml
provid
basi
develop
new
antivir
therapi
defilippi
et
al
wang
et
al
attract
target
viral
gene
essenti
viru
replic
host
gene
essenti
viru
entri
play
essenti
role
viru
life
cycl
rna
virus
hiv
potenti
region
viral
genom
target
sirna
shrna
silenc
gene
relev
viral
diseas
hiv
dave
pomerantz
hepat
wilson
et
al
sever
acut
respiratori
syndrom
sar
associ
coronaviru
zhang
et
al
achiev
use
rnai
case
hiv
silenc
primari
hiv
receptor
chemokin
c
c
motif
receptor
sirna
result
prevent
viral
entri
human
peripher
blood
lymphocyt
qin
et
al
primari
haematopoiet
stem
cell
hepat
c
sirna
silenc
led
reduct
detect
viru
infect
cell
randal
et
al
randal
rice
use
sirna
target
surfac
antigen
region
hepat
b
viru
hbv
giladi
et
al
show
viral
mrna
viral
antigen
viral
genom
dna
significantli
reduc
vitro
vivo
similarli
shrna
use
inhibit
express
hepat
b
viru
surfac
antigen
cell
decreas
level
secret
antigen
case
sar
recent
shown
sarsassoci
coronaviru
replic
effici
inhibit
use
sirna
two
sar
viral
polymeras
similarli
zhang
et
al
use
cytotox
vero
cell
surrog
marker
sarsviru
infect
show
sirna
transfect
could
effect
inhibit
coronaviru
replic
target
infecti
virus
use
rnai
also
pursu
instanc
possibl
induc
apoptosi
primari
patient
tumour
sampl
target
gene
human
papilloma
viru
butz
et
al
plasmiddriven
sirna
specif
west
nile
viru
effect
suppress
viral
transcript
infecti
virion
product
cell
line
mccown
et
al
addit
sirna
specif
conserv
region
influenza
viru
genom
protect
cell
line
embryon
chicken
egg
infect
ge
et
al
respiratori
syncyti
viru
rsv
ubiquit
environ
common
caus
bronchiolitisassoci
hospit
children
immunocompromis
adult
mcbride
monick
et
al
show
rsv
infect
activ
erk
via
epiderm
growth
factor
receptor
egfr
lead
pronounc
inflamm
prolong
surviv
infect
cell
inflamm
resolv
apoptosi
induc
infect
immort
primari
lung
epitheli
cell
target
egfr
use
sirna
anoth
studi
rudd
et
al
show
tolllik
receptor
mediat
inflammatori
cytokin
chemokin
product
rsvinfect
epitheli
cell
use
sirna
target
tolllik
receptor
complement
experi
vitro
zhang
et
al
show
mice
treat
intranas
sirna
nanoparticl
target
viral
gene
infect
rsv
show
substanti
decreas
viru
titer
lung
decreas
inflamm
airway
reactiv
compar
control
contrast
virus
bacteria
gener
amen
silenc
sirna
mainli
replic
outsid
host
cell
lack
necessari
machineri
lieberman
et
al
howev
might
still
possibl
reduc
morbid
mortal
lifethreaten
bacteri
infect
silenc
host
gene
involv
aspect
immun
respons
lead
advers
consequ
host
gene
involv
mediat
bacteri
invas
instanc
reduc
express
proinflammatori
cytokin
tumour
necrosi
factor
tnfa
lessen
septic
shock
mice
treat
lipopolysaccharid
lp
without
jeopard
develop
protect
immun
sorensen
et
al
knockdown
murin
lung
epitheli
cell
inhibit
pseudomona
aeruginosa
major
pulmonari
pathogen
cystic
fibrosi
patient
invas
lipid
raftdepend
mechan
zaa
et
al
despit
rapid
expans
medic
technolog
recent
year
malaria
still
claim
estim
million
death
per
year
casualti
occur
subsaharan
africa
vernick
water
latter
part
centuri
alarm
increas
number
case
malaria
report
indian
subcontin
southeast
asia
south
america
malaney
et
al
chloroquin
remain
gold
standard
treatment
malaria
today
howev
chloroquin
resist
grow
concern
verdrag
caus
agent
diseas
plasmodium
falciparum
member
intracellular
protozoan
famili
apicomplexa
kumar
et
al
kumar
et
al
silenc
serin
threonin
protein
phosphatas
parasit
show
enzym
play
essenti
role
life
cycl
therefor
offer
potenti
target
drug
develop
downsid
approach
highli
conserv
throughout
evolut
toxic
side
effect
expect
unless
specif
variant
protein
identifi
find
machineri
rnai
exist
anophel
gambia
princip
malaria
vector
africa
hoa
et
al
allow
insight
effect
mosquito
gene
plasmodium
develop
osta
et
al
addit
open
possibl
develop
transgen
insect
vector
innat
resist
develop
growth
p
falciparum
osta
et
al
anoth
protozoan
parasit
entamoeba
histolytica
caus
human
amoebiasi
vayssi
et
al
second
lead
caus
death
worldwid
due
protozoan
infect
insid
host
parasit
invad
intestin
mucosa
caus
dysenteri
travel
circulatori
system
liver
caus
develop
abscess
petri
use
rnai
knockdown
vayssi
et
al
demonstr
gtubulin
essenti
microtubul
nucleat
cycl
parasit
importantli
primari
amino
acid
sequenc
protein
homolog
ident
human
homolog
therefor
specif
sirna
may
develop
destroy
parasit
gtubulin
leav
host
counterpart
untouch
discoveri
develop
inhal
antisens
oligonucleotid
ball
et
al
suggest
deliveri
sirna
molecul
lung
might
viabl
approach
treatment
respiratori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
copd
global
health
problem
fourth
lead
caus
death
unit
state
alon
murphi
goblet
cell
hyperplasia
mucu
hypersecret
promin
featur
copd
especi
exacerb
pistelli
et
al
shao
et
al
show
specif
knock
transform
growth
factor
tgf
product
via
sirna
human
airway
epitheli
cell
express
epiderm
growth
factor
receptor
egfr
significantli
reduc
lead
diminish
mucu
product
anoth
clinic
manifest
asthma
copd
chronic
inflamm
injuri
airway
parenchym
structur
lung
tgfh
thought
play
key
role
rennard
sacco
et
al
tgfh
mediat
divers
rang
cellular
process
includ
cell
prolifer
differenti
wound
heal
angiogenesi
blobe
et
al
murin
lung
fibrosi
model
gurujeyalakshmi
giri
interferon
ifn
g
downregul
tgfh
express
improv
fibrosi
wen
et
al
identifi
tgfh
suppress
mediat
via
smad
protein
target
knockdown
smad
sirna
revers
suppress
jefferi
et
al
use
smad
sirna
show
antiprolif
prodifferenti
effect
bone
morphogenet
protein
lung
fibroblast
depend
fibroblast
prolifer
differenti
migrat
contribut
characterist
pulmonari
vascular
remodel
seen
primari
pulmonari
hypertens
pph
recruit
neutrophil
lung
central
host
defens
invad
pathogen
howev
trauma
patient
expos
secondari
infectioussept
challeng
neutrophil
target
sequestr
result
acut
lung
injuri
ali
contribut
high
morbiditymort
seen
popul
ali
progress
syndrom
exagger
inflammatori
respons
central
caus
lung
injuri
lomasneira
et
al
press
use
mous
model
haemorrhag
shock
analys
effect
postshocksepsi
intratrach
instil
sirna
target
keratinocytederiv
chemokin
kc
macrophageinflammatori
develop
ali
result
show
local
product
regul
neutrophil
influx
increas
endotheli
cell
ec
permeabl
central
pathophysiolog
ali
silenc
sphingosin
express
use
sirna
finigan
et
al
show
activ
protein
c
mediat
ec
permeabl
via
transactiv
potent
barrierenhanc
receptor
airway
epithelium
provid
barrier
extern
intern
milieu
lung
respons
variou
environment
factor
well
activ
particip
inflammatori
immun
respons
epitheli
cell
respond
cytokin
chemokin
hormon
growth
factor
inflammatori
mediat
postul
play
crucial
role
airway
diseas
asthma
cookson
howev
intracellular
signal
pathway
involv
regul
epitheli
cell
poorli
understood
use
sirna
target
syk
tyrosin
kinas
ulanova
et
al
show
syk
regard
attract
antiinflammatori
target
particip
h
integrin
signal
inflammatori
respons
airway
epitheli
cell
cellspecif
target
sirna
import
issu
consid
consid
therapi
regard
lung
gou
et
al
abl
get
rnai
silenc
specif
rat
lung
alveolar
epitheli
type
ii
cell
use
adenovir
vector
contain
variou
shrna
control
surfact
protein
c
promot
vitro
vivo
given
abil
rnai
silenc
diseaseassoci
gene
includ
allel
variant
dykxhoorn
et
al
tissu
cultur
anim
model
surpris
lot
interest
develop
rnaibas
reagent
clinic
applic
wall
shi
current
dozen
biotechnolog
compani
develop
clinic
applic
sirna
variou
human
diseas
howard
tabl
addit
eas
synthesi
low
product
cost
compar
protein
antibodi
therapi
data
indic
sirna
favour
pharmacokinet
properti
deliv
wide
rang
organ
braasch
et
al
howev
blood
stabil
deliveri
poor
intracellular
uptak
nonspecif
immun
stimul
still
present
signific
challeng
develop
rnai
reagent
clinic
use
although
sirna
molecul
appear
resist
nucleas
degrad
antisens
molecul
bertrand
et
al
serum
nucleas
degrad
sirna
paroo
corey
dykxhoorn
lieberman
result
number
group
investig
use
chemic
modif
improv
stabil
protect
nucleas
degrad
fougerol
et
al
although
phosphothio
modif
import
success
antisens
applic
vivo
crook
studi
shown
toxic
loss
silenc
activ
problem
phosphothio
sirna
braasch
et
al
harborth
et
al
result
sever
group
investig
use
altern
backbon
nucleotid
modif
address
problem
hall
et
al
show
boranophosph
sirna
effect
silenc
phosphothio
sirna
time
nucleas
resist
unmodifi
sirna
addit
boranophosph
sirna
potent
unmodifi
sirna
appear
act
standard
rnai
pathway
elmen
et
al
modifi
sirna
synthet
rnalik
highaffin
nucleotid
analogu
lock
nucleic
acid
lna
show
incorpor
modest
number
lna
modif
significantli
enhanc
serum
halflif
sirna
stabil
duplex
structur
affect
gene
silenc
similarli
allerson
et
al
show
sirna
contain
nucleotid
display
enhanc
stabil
also
show
increas
potenc
experi
indic
gene
silenc
sirna
vivo
impair
layzer
et
al
altern
backbon
modif
group
improv
stabil
sirna
improv
deliveri
vivo
complex
polyethyleneimin
pei
urbanklein
et
al
atelocollagen
minakuchi
et
al
cholesterol
soutschek
et
al
anoth
approach
biodegrad
poli
llactidecoglycolid
copolym
microspher
shown
give
sustain
releas
sirna
molecul
site
administr
mice
even
day
postadministr
khan
et
al
number
differ
approach
develop
vivo
deliveri
sirna
fig
among
approach
tri
rodent
rapid
infus
hydrodynam
inject
sirna
achiev
best
deliveri
albeit
limit
set
vascular
tissu
lewi
wolff
primari
recipi
tissu
liver
success
transgen
deliveri
express
hepatocyt
obtain
liu
et
al
sever
group
use
techniqu
success
introduc
sirnaor
shrnaexpress
construct
mice
achiev
effici
deliveri
subsequ
silenc
target
gene
mccaffrey
et
al
giladi
et
al
zender
et
al
hamar
et
al
xu
et
al
key
constraint
method
deliveri
tend
restrict
highli
vascular
tissu
liver
spleen
kidney
addit
techniqu
current
viabl
method
deliveri
human
clinic
studi
effort
develop
method
target
tissuespecif
deliveri
lipidbas
strategi
vivo
applic
devis
sioud
sorensen
lipidbas
formul
use
extens
cell
cultur
experi
attribut
optim
uptak
cell
cultur
differ
vivo
princip
issu
cation
natur
lipid
use
cell
cultur
lead
aggreg
use
anim
result
rapid
serum
clearanc
lung
accumul
despit
increas
number
report
cite
success
lipidmedi
deliveri
sirna
vivo
ge
et
al
hassani
et
al
zhang
et
al
subcutan
mous
tumour
model
intraperiton
administr
sirna
complex
pei
led
deliveri
intact
sirna
tumour
urbanklein
et
al
schiffel
et
al
construct
selfassembl
nanoparticl
sirna
pei
pegyl
argglyasp
peptid
ligand
attach
distal
end
polyethylen
glycol
peg
mean
target
tumour
neovasculatureexpress
integrin
intraven
administr
tumourbear
mice
result
select
tumour
uptak
sirna
sequencespecif
inhibit
protein
express
within
tumour
inhibit
tumour
angiogenesi
growth
rate
result
show
sirna
target
two
level
tumour
tissueselect
deliveri
via
nanoparticl
ligand
gene
pathway
select
via
sirna
oligonucleotid
improv
deliveri
sirna
human
liver
cell
without
transfect
agent
lorenz
et
al
synthes
lipophil
sirna
conjug
deriv
cholesterol
lithochol
acid
lauric
acid
lipid
moieti
coval
link
rna
use
phosphoramidit
chemistri
shown
downregul
express
lacz
express
construct
conjug
cholesterol
sens
strand
sirna
mean
pyrrolidin
linker
soutschek
et
al
markedli
improv
pharmacolog
properti
sirna
molecul
besid
resist
nucleas
degrad
cholesterol
attach
stabil
sirna
molecul
blood
increas
bind
human
serum
albumin
increas
uptak
sirna
molecul
liver
massaro
et
al
show
sirna
could
effect
deliv
pulmonari
alveoli
mice
use
pulmonari
surfact
lipoprotein
line
alveoli
deliveri
vehicl
intravascular
deliveri
sirna
molecul
attract
inher
simplic
use
deliv
sirna
mice
attempt
protect
mice
fulmin
hepat
use
sirna
fa
receptor
song
et
al
administ
fa
sirna
intraven
inject
mice
period
effect
persist
day
protect
mice
experiment
induc
liver
fibrosi
hagstrom
et
al
inject
nake
sirna
distal
vein
limb
transient
isol
tourniquet
blood
pressur
cuff
abl
show
effici
repeat
deliveri
nucleic
acid
muscl
cell
myofib
throughout
limb
muscl
mammal
rapid
inject
suffici
volum
enabl
extravas
sirna
myofib
high
level
transgen
express
skelet
muscl
achiev
small
larg
anim
appar
minim
toxic
approach
deliveri
sirna
vivo
describ
local
deliveri
sirna
eye
use
show
sirna
target
vascular
endotheli
growth
factor
vegf
pathway
could
therapeut
benefici
neovascularizationrel
eye
diseas
kim
et
al
electropor
use
deliv
sirna
kidney
takabatak
et
al
press
brain
akaneya
et
al
eye
matsuda
cepko
muscl
golzio
et
al
skin
zhang
et
al
rodent
topic
gel
also
use
deliv
sirna
cell
could
open
way
dermatolog
applic
well
treatment
cervic
cancer
jiang
et
al
intraderm
administr
nucleic
acid
via
gene
gun
use
deliv
sirna
vivo
enhanc
cancer
vaccin
potenc
kim
et
al
ultrasound
taniyama
et
al
could
also
potenti
use
deliv
sirna
although
report
current
clinic
applic
gentl
method
deliveri
sirna
molecul
similar
develop
antisens
molecul
inhal
cream
formul
oral
crook
would
prefer
sever
group
investig
use
direct
inject
viral
vector
vivo
deliveri
sirna
aav
shrna
vector
inject
directli
midbrain
neuron
adult
mice
result
silenc
tyrosin
hydroxylas
gene
near
site
inject
sever
week
hommel
et
al
result
behaviour
chang
includ
motor
perform
deficit
reduc
respons
psychostimul
intracerebellar
inject
aav
vector
express
shrna
direct
mutant
variant
profoundli
improv
motor
coordin
restor
cerebellar
morpholog
resolv
characterist
inclus
purkinj
cell
mous
model
neurodegen
disord
spinocerebellar
ataxia
altern
inject
banerjea
et
al
use
ex
vivo
approach
gener
lymphocyt
macrophag
use
lentivir
vector
antirev
sirna
construct
introduc
hematopoiet
progenitor
cell
sirnatransduc
progenitor
cell
allow
matur
macrophag
vitro
tcell
vivo
sever
combin
immunodefici
scid
mice
transplant
human
thymu
fetal
liver
graft
phenotyp
normal
tcell
macrophag
display
characterist
surfac
marker
obtain
vitro
challeng
sirnaexpress
macrophag
tcell
macrophagetrop
tcelltrop
respect
show
mark
viral
resist
despit
success
report
viralmedi
insert
mutagenesi
patient
receiv
retrovirusmedi
gene
therapi
treatment
xlink
sever
combin
immunodefici
xscid
haceinbey
abina
et
al
marshal
rais
concern
safeti
use
viral
vector
therapi
care
select
sequenc
need
maximis
gene
silenc
minimis
offtarget
nonspecif
effect
although
initi
thought
laserlik
specif
offtarget
effect
sirna
becom
evid
jackson
et
al
couzin
jackson
linsley
scacheri
et
al
sirna
duplex
may
target
mrna
molecul
sequenc
homolog
wide
observ
sirna
toler
mismatch
mrna
target
time
retain
good
silenc
capac
yu
et
al
pusch
et
al
vicker
et
al
case
sirna
toler
sever
mismatch
saxena
et
al
even
toler
mismatch
act
singlestrand
antisens
sirna
holen
et
al
addit
domain
sirna
toler
mismatch
other
schwarz
et
al
saxena
et
al
also
demonstr
toler
gu
wobbl
pair
rna
oligo
target
rna
investig
effect
mismatch
sirna
offtarget
activ
snove
holen
analys
publish
sirna
sequenc
found
around
could
potenti
elicit
nonspecif
effect
microarray
technolog
use
examin
offtarget
effect
result
contradictori
studi
find
high
specif
sirna
effect
chi
et
al
semizarov
et
al
other
jackson
et
al
persengiev
et
al
anoth
consider
offtarget
activ
might
actual
repres
genuin
physiolog
knockon
effect
specif
target
knockdown
certain
biochem
pathwayscascad
therefor
activ
interpret
care
context
biolog
system
question
result
rnai
studi
confirm
use
complementari
approach
use
multipl
sirna
duplex
recent
data
suggest
sirna
shrna
induc
subset
gene
involv
interferon
respons
mammalian
cell
sledz
et
al
show
sirna
activ
jak
stat
pathway
induc
global
upregul
ifnstimul
gene
mediat
dsrnadepend
protein
kinas
pkr
howev
find
also
confirm
sirnainduc
knockdown
independ
ifn
system
anoth
report
bridg
et
al
link
activ
interferon
express
vector
carri
shrna
hairpin
sirna
alon
elicit
respons
complementari
studi
heidel
et
al
show
possibl
administ
nake
synthet
dna
mice
downregul
endogen
exogen
target
without
induc
ifn
respons
addit
ifn
respons
report
sishrna
initi
immun
activ
macrophag
dendrit
cell
tolllik
receptor
toll
receptor
recogn
exogen
nucleic
acid
kariko
et
al
current
unclear
often
sishrna
trigger
effect
cell
condit
favour
respons
immunosuppress
select
differ
administr
rout
dose
vector
use
tissuespecif
promot
vector
modif
investig
although
rnai
plant
associ
de
novo
rnadirect
dna
methyl
rddm
hamilton
et
al
experi
suggest
may
case
mammalian
cell
park
et
al
although
effect
epigenet
modif
histon
modif
yet
assess
rel
short
time
rnai
rapidli
progress
becom
key
experiment
tool
analysi
gene
function
target
valid
mammalian
system
vitro
vivo
result
abl
cite
small
portion
thousand
paper
alreadi
publish
area
howev
hope
suffici
thorough
coverag
give
reader
insight
mani
use
import
technolog
put
well
highlight
current
limit
potenti
rnai
therapeut
strategi
effect
rnai
reagent
improv
glean
biolog
rnai
mammalian
system
improv
stabil
deliveri
reduct
offtarget
nonspecif
effect
made
although
still
fledgl
area
clinic
applic
rnai
build
lesson
learn
clinic
use
antisens
molecul
deliveri
viral
otherwis
target
specif
sirna
key
unlock
transit
rnaibas
gene
therapi
great
potenti
cancer
infecti
diseas
well
genet
diseas
due
domin
genet
effect
eg
huntington
chorea
amyotroph
later
sclerosi
use
induc
rnai
system
particularli
attract
clinic
set
abil
revers
sirna
treatment
simpli
withdraw
induc
agent
would
allow
treatment
termin
appropri
